World class leaders
Adaptin is led by a team of highly skilled executives and scientists
The management team at Adaptin Bio has extensive experience in biotechnology and pharmaceutical industries. Their backgrounds include leadership and executive roles in research and development, clinical operations, and business strategy.
Collectively, they bring expertise in oncology, precision medicine, drug development, and commercialization, with a proven track record of advancing innovative therapies from concept to market. Notably, the team previously worked at Chelsea Therapeutics, where they played instrumental roles in the company’s success and eventual exit. Their combined skills and experience are instrumental in driving Adaptin Bio’s mission to develop cutting-edge treatments for cancer and other serious diseases.
Early in his career he was a faculty in the Department of Pharmacology in College of Medicine at the University of Saskatchewan, where he obtained his Ph.D. in Clinical Pharmacology. During his longstanding career in pharmaceutical development, Simon had played key roles in the successful development and commercial of multiple proprietary pharmaceutical products including Tasmar®, Pegasys®, Copegus®, Northera® and Klisyri®. In addition to his Ph.D., Simon obtained a Master of Science in Toxicology from Concordia University, a Joint Honors Bachelor degree in Environmental Studies/Biology from the University of Waterloo, and he completed the Roche-sponsored Pharmaceutical Executive Management Program at Columbia Business School.